about
Purinergic Signaling in BoneAcidosis is a key regulator of osteoblast ecto-nucleotidase pyrophosphatase/phosphodiesterase 1 (NPP1) expression and activity.Purinergic signalling and bone remodelling.Strontium potently inhibits mineralisation in bone-forming primary rat osteoblast cultures and reduces numbers of osteoclasts in mouse marrow culturesOptimisation of the differing conditions required for bone formation in vitro by primary osteoblasts from mice and rats.Generation of rodent and human osteoblasts.Extracellular ATP released by osteoblasts is a key local inhibitor of bone mineralisation.Allopurinol and oxypurinol promote osteoblast differentiation and increase bone formation.Purinergic signalling in the musculoskeletal system.Purinergic signalling in osteoblasts.The role of purinergic signalling in the musculoskeletal system.Pyrophosphate: a key inhibitor of mineralisation.Chronic administration of Glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice.Design and fabrication of 3D-printed anatomically shaped lumbar cage for intervertebral disc (IVD) degeneration treatment.Tumour-derived alkaline phosphatase regulates tumour growth, epithelial plasticity and disease-free survival in metastatic prostate cancer.Kidins220/ARMS mediates the integration of the neurotrophin and VEGF pathways in the vascular and nervous systems.Lack of effect of adenosine on the function of rodent osteoblasts and osteoclasts in vitro.Stable sulforaphane protects against gait anomalies and modifies bone microarchitecture in the spontaneous STR/Ort model of osteoarthritis.Mineralisation of collagen rich soft tissues and osteocyte lacunae in Enpp1(-/-) mice.Hypoxia stimulates vesicular ATP release from rat osteoblasts.Activation of the P2Y2 receptor regulates bone cell function by enhancing ATP release.Inhibition of arterial medial calcification and bone mineralization by extracellular nucleotides: The same functional effect mediated by different cellular mechanisms.Role of the P2Y13 receptor in the differentiation of bone marrow stromal cells into osteoblasts and adipocytes.Inhibition of osteoblast function in vitro by aminobisphosphonates.Strontium and osteoblast function.Acidosis inhibits bone formation by osteoblasts in vitro by preventing mineralization.The regulation of osteoblast function and bone mineralisation by extracellular nucleotides: The role of p2x receptors.Hypothermia inhibits osteoblast differentiation and bone formation but stimulates osteoclastogenesis.Hypoxia inhibits the growth, differentiation and bone-forming capacity of rat osteoblasts.Metabolic properties of the osteoclast.Spina bifida-predisposing heterozygous mutations in Planar Cell Polarity genes and Zic2 reduce bone mass in young mice.Clopidogrel (Plavix), a P2Y12 receptor antagonist, inhibits bone cell function in vitro and decreases trabecular bone in vivo.Hypoxia is a major stimulator of osteoclast formation and bone resorption.Rodent osteoclast cultures.The P2Y(6) receptor stimulates bone resorption by osteoclasts.Hypoxia stimulates osteoclast formation from human peripheral blood.Osteoblast responses to nucleotides increase during differentiation.Editorial overview: Musculoskeletal: Where are we with treating musculoskeletal disorders?Inhibition of vascular smooth muscle cell calcification by ATP analogues
P50
Q27496045-0D3C8C2A-1573-4FC1-A510-4E233F652514Q33288810-81A6CAF8-A5C6-4824-A7C1-010B15F8D9F6Q34021414-C90CD4CA-6770-4FFD-A6BC-0E1F36CF43DBQ34250624-8A2BF743-0630-41F6-896D-0948C210F27CQ34350355-B4B506D8-5FF6-4A1A-852E-D3C5FF1B9E3CQ34502177-D3949C4D-97F5-4C55-82E4-0AD204F1FD4EQ34852675-AD4D12E4-B2BE-4EFA-AC49-5D573B279594Q36791027-4E053EB0-3360-4B02-A707-BBD600BA80E2Q37468714-4C1BAEF0-9AEE-45E4-8FAB-9BC9612FE61AQ37971510-658BD46C-1995-47C4-A24A-351115E0678BQ38483890-46CFBA1E-5462-4988-95FD-71AD3BC1D224Q38803194-75F10D62-48C7-4298-9A63-21450D157022Q38840315-A4192494-E2CD-447D-9587-985D5358B902Q38840373-BB80F277-A57D-4EB4-8246-006E55931BD7Q39072065-2555EF61-E46C-4223-8001-B4CFC482B304Q40577983-D1E8D8D3-9A3F-400F-8C5C-5D9754EFC298Q40932223-CFFE164D-B102-4932-AE67-9880E42B2A1BQ41634814-38F142F0-68F4-4A0A-A347-4FC0B5F5E2C1Q42272777-F56242D3-51B7-471F-9F6E-CF35B4B7937CQ42450321-E285ECC3-81A9-402F-A855-7EA239CF4F3AQ42508641-A747640B-EE3A-4ED5-871F-686B9D3961BBQ42516251-54E6F3C4-A9F8-413E-8A16-DD7F635BD112Q45021528-677BA4CF-A703-4201-B607-67476F25E828Q45891384-C2C5B2CA-CE48-4D6C-A92A-F76F838FA3EDQ46281381-61CA3125-04BD-4019-BF96-C82478BE5399Q46283308-7713606B-F7BA-4E52-AE6D-D7D1D537742AQ46290472-08479317-BBD4-4B9C-BE7A-06F999DC795CQ46683208-29307042-C56C-4CA3-BD8F-63DA4DE5DB5CQ46985036-324F2FDF-7DE0-49A3-BF51-9C12BEAF90E7Q49598130-D20FF906-6B0D-465A-A813-D594DC2B9668Q49789426-AA546D56-7D0C-4043-AEE7-1C10D6E00BB0Q50508654-344F0BB7-E9A8-4C2A-8538-7F18F3ACE119Q51671770-4816F777-D2AE-41BC-B772-C6EEF9DBE462Q51846748-316ED320-7523-450B-8A0D-9C0A316BB2B3Q51858178-49362B8C-9CD1-4B75-84CD-C243AF3F793CQ51906180-6A18AA8E-EAE9-48F0-A6E9-01DD074CDD0CQ52020613-1B19F506-06A8-421C-8485-30561C0551B2Q64464768-C232072B-12F9-402D-85DF-2078EFBA71D8Q92139684-6B19227F-46A3-4559-B59C-D2A114F4E7F2
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Isabel R Orriss
@es
Isabel R Orriss
@nl
Isabel R Orriss
@sl
Isabel R. Orriss
@en
type
label
Isabel R Orriss
@es
Isabel R Orriss
@nl
Isabel R Orriss
@sl
Isabel R. Orriss
@en
prefLabel
Isabel R Orriss
@es
Isabel R Orriss
@nl
Isabel R Orriss
@sl
Isabel R. Orriss
@en
P106
P1153
9040660500
P21
P31
P496
0000-0002-7847-050X